Fresenius Medical Care AG & Co. KGaA (DE:FME)
XETRA:FME
Top Page
Fresenius Medical Care AG & Co. KGaA
(XETRA:FME)
Select Model
Select Model
Rating:58Neutral
Price Target:
€41.00
▲(1.64% Upside)
Action:ReiteratedDate:02/27/26
The score is driven primarily by mixed financial performance: a 2025 earnings rebound is offset by contracting revenue, weaker free-cash-flow momentum, and higher debt. Valuation is a relative positive with a low P/E and solid dividend yield, while technical signals are neutral and do not add strong support.
Positive Factors
Market leadership and integrated model
Fresenius’ scale and integrated clinic-plus-products model creates durable barriers: a large clinic network, recurring consumable demand, purchasing scale and long-term contracts produce steady service revenues and high switching costs, supporting stable cash flows over time.
Negative Factors
Revenue contraction
Two consecutive years of flat-to-declining revenue, including a ~7.6% fall in 2025, point to structural headwinds such as pricing, reimbursement or volume pressure. Persistent top-line weakness limits operating leverage and constrains durable growth and reinvestment capacity.
Read all positive and negative factors
Positive Factors
Negative Factors
Market leadership and integrated model
Fresenius’ scale and integrated clinic-plus-products model creates durable barriers: a large clinic network, recurring consumable demand, purchasing scale and long-term contracts produce steady service revenues and high switching costs, supporting stable cash flows over time.
Read all positive factors
Fresenius Medical Care AG & Co. KGaA (FME) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€11.72B
Dividend Yield3.54%
Average Volume (3M)529.60K
Price to Earnings (P/E)12.1
Beta (1Y)0.58
Revenue Growth2.10%
EPS Growth9.19%
CountryDE
Employees112,035
SectorGeneral
Sector StrengthN/A
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)1.44
Shares Outstanding293,413,450
10 Day Avg. Volume492,004
30 Day Avg. Volume529,597
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.89
Price to Sales (P/S)0.60
P/FCF Ratio6.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€38.34Price Target Upside-4.96% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering11
EPS Forecast (FY)4.08
Revenue Forecast (FY)€19.42B
Fresenius Medical Care AG & Co. KGaA Business Overview & Revenue Model
Company Description
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpati...
How the Company Makes Money
Fresenius Medical Care generates revenue primarily through two key segments: Products and Services. The Products segment includes the sale of dialysis machines, dialyzers, and other related medical equipment, which are sold to hospitals and health...
Fresenius Medical Care AG & Co. KGaA Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 19.63B | 19.34B | 19.45B | 19.40B | 17.62B |
| Gross Profit | 5.03B | 4.76B | 4.93B | 5.31B | 5.08B |
| EBITDA | 3.34B | 3.21B | 2.93B | 3.22B | 3.42B |
| Net Income | 978.00M | 537.91M | 499.00M | 673.40M | 969.31M |
Balance Sheet | |||||
| Total Assets | 31.00B | 33.57B | 33.93B | 35.75B | 34.37B |
| Cash, Cash Equivalents and Short-Term Investments | 1.73B | 1.45B | 1.54B | 1.44B | 1.62B |
| Total Debt | 13.70B | 10.98B | 12.05B | 13.21B | 13.32B |
| Total Liabilities | 16.72B | 17.80B | 19.10B | 20.30B | 20.39B |
| Stockholders Equity | 13.31B | 14.58B | 13.62B | 15.45B | 13.98B |
Cash Flow | |||||
| Free Cash Flow | 1.77B | 1.69B | 1.94B | 1.44B | 1.64B |
| Operating Cash Flow | 2.68B | 2.39B | 2.63B | 2.17B | 2.49B |
| Investing Cash Flow | -693.55M | -84.94M | -544.23M | -734.73M | -1.20B |
| Financing Cash Flow | -1.43B | -2.57B | -1.86B | -1.62B | -1.02B |
Fresenius Medical Care AG & Co. KGaA Technical Analysis
Positive
40.34
Price Trends
39.48
Positive
39.52
Positive
41.98
Negative
Market Momentum
0.11
Negative
59.88
Neutral
86.13
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:FME, the sentiment is Positive. The current price of 40.34 is above the 20-day moving average (MA) of 39.04, above the 50-day MA of 39.48, and below the 200-day MA of 41.98, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 59.88 is Neutral, neither overbought nor oversold. The STOCH value of 86.13 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:FME.
Fresenius Medical Care AG & Co. KGaA Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €2.32B | 17.81 | 6.77% | 1.50% | 7.82% | -19.80% | |
58 Neutral | €11.72B | 12.14 | 7.26% | 3.54% | 2.10% | 9.19% | |
58 Neutral | €48.63B | 20.44 | 9.02% | 1.82% | 1.47% | 9.64% | |
57 Neutral | €42.14B | 27.87 | 11.65% | 2.13% | 4.53% | 10.12% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
48 Neutral | €39.41B | -10.04 | -12.24% | 0.31% | -1.87% | 77.51% | |
46 Neutral | €13.24B | 110.19 | 5.01% | 0.30% | 5.82% | 59.90% |
* General Sector Average
DE:FME
Fresenius Medical Care AG & Co. KGaA
40.34
-2.03
-4.80%
DE:BAYN
Bayer
40.12
19.33
92.98%
DE:AFX
Carl Zeiss Meditec
25.94
-29.41
-53.14%
DE:MRK
Merck KGaA
111.85
-3.57
-3.09%
DE:SRT3
Sartorius
214.40
24.80
13.08%
DE:SHL
Siemens Healthineers AG
37.77
-5.49
-12.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.